Depressive symptoms are associated with poor glycemic control among women with type 2 diabetes mellitus

Carlos Góis1,2*, Tiago Antunes Duarte1, Sofia Paulino1, João Filipe Raposo3,4, Isabel do Carmo2 and António Barbosa1,2

Abstract

Objective: In patients with type 2 diabetes mellitus, depressive symptoms may be associated with metabolic deterioration. The impact of sex on this association is unclear. The aim of this study is to analyze the relationship between depression and metabolic control by sex. The data presented is the side product of the clinical investigation by Rui Duarte, MD, Treatment Response in Type 2 Diabetes Patients with Major Depression from 2007.

Results: A sample of 628 outpatients with type 2 diabetes mellitus was taken from a specialized diabetes outpatient clinic. In a univariate analysis: women’s glycohemoglobin mean levels were 8.99% whereas men’s were 8.41% and the difference was statistically significant. The proportion of women (34.3%) with pathological levels of depression (Hospital Anxiety Depression Scale score \( \geq 8 \)) was significantly higher than men’s (15.2%). A linear regression analysis performed by sex and controlling for demographic, clinical and psychological variables, showed poorer metabolic control in women with depressive symptoms. No association was observed in men. These results support depression as a predictor for poor metabolic control in women and the need for detecting depressive symptoms when glycemic levels deteriorate.

Keywords: Type 2 diabetes mellitus, Depression, Glycemic control, Sex

Introduction

Comorbidity between diabetes and depression is common [1] and sex differences in type 2 diabetes mellitus (T2DM) have been reported frequently [2].

A recent prevalence study of the Portuguese population demonstrated that the proportion of undiagnosed T2DM patients is 43.6% with a point prevalence of 11.7% with a significant difference between men (14.2%) and women (9.5%) [3]. Another recent epidemiological survey found a prevalence of depression disorders in Portugal around 7.9%, women being at a higher risk of developing depression than men (OR = 2.30) [4]. There are no studies reporting the prevalence of diabetes and depression comorbidity in the Portuguese population.

Although estrogens lower the risk of coronary heart disease, diabetes eliminates that protective effect on women [5]. Estrogen replacement therapy showed a preventive effect on T2DM incidence in postmenopausal women [6] and was also associated with a decrease in depressive symptoms in perimenopausal women [7].

Negative coping strategies such as resignation, protest and isolation, were reported to be more prevalent in women with T2DM when compared to men [8]. Women also presented more difficulty on diet management and self-monitoring of blood glucose. They experienced their disease as an unforeseeable setback [9, 10] thus being less likely to reach glycemic goals with insulin treatment [11].

In women without diabetes, depressive symptoms are associated with a higher risk for metabolic syndrome. A greater waist circumference, higher fasting blood
glucose, higher diastolic blood pressure, lower HDL-
cholesterol and higher salivary cortisol were observed in
women with depressive symptoms. No similar pattern
was observed in men [12–14].

The few studies evaluating depressive symptoms
by sex as associated with poorer glycemic control in
T2DM showed conflicting results [15–18]. The finding
of a sex difference would translate into better-adapted
approaches, such as emphasizing the regular screening
for depression in women with diabetes [19].

The present study aimed at detecting whether the presen-
ce of depressive symptoms was associated with poor
glycemic control according to sex in a population with
T2DM from a Portuguese diabetes clinic.

Main text

Methods

Patients

A screening protocol to detect depression and anxiety
states in patients with T2DM was undertaken at the Por-
tuguese Diabetes Association (APDP) and included in a
multicenter screening study whose results were published
elsewhere [20]. This protocol aimed to provide and evalu-
ate specific clinical care for the comorbidity T2DM and
depression. Inclusion criteria were age between 18 and
65 years; at least 6 months of T2DM diagnosis (type 1
diabetes (T1DM) was excluded); at least a 3 months’ fol-
low-up at APDP; regular hemoglobin A1c (HbA1c) test-
ing; and ability to understand and fill up questionnaires.

Portugal is a small southern European country with
10 million inhabitants. APDP is a private social solidar-
ity institution, specialized in outpatient diabetes treating,
founded in 1926 in Lisbon, and to where several general
practitioners from southern Portugal sent patients regu-
larly. More than 15,000 persons with T2DM and 4,000
with T1DM are yearly followed up at APDP. It also pro-
vides regular training on diabetes and patient education
to nurses and medical doctors.

Methods

While waiting for their diabetes consultation, patients
were approached and selected by trained clinical psy-
chologists taking into account the inclusion criteria. Elig-
ible patients were consecutively invited to participate and
those who accepted were given a brief explanation about
the negative influence of the comorbidity between dia-
abetes and depression on health outcomes. Socio-demo-
graphic and clinical data, namely body mass index (BMI),
HbA1c level, diabetes type, therapy and antidepressant
medication, were collected. Chronic complications (retin-
opathy, nephropathy, neuropathy and cardiovascular) due
to diabetes were identified from the patient’s medical his-
tory, physical findings and automated laboratory data.

Patients filled up the Portuguese version of the Hospi-
tal Anxiety Depression Scale (HADS) [21, 22]. HADS is
a self-report Likert scale (0–3) used in previous studies
for detection of depression and anxiety symptoms, con-
sisting of 14 questions, 7 for anxiety and 7 for depression.
Each sub-scale score ranges from 0 to 21, higher scores
representing more severe symptoms. A score ≥ 8 on any
of the sub-scales is considered pathological [22]. Only the
depression symptoms sub-scale of HADS was used in the
present study.

The HbA1c levels were determined at the APDP using
an ion-exchange high-performance liquid chromatog-
raphy in a BIO-RAD Variant II turbo kit. According
to the manufacturing data, normal range is 4.9–6.2%
(30–44 mmol/mol).

Statistical analysis

Results are presented as the mean ± standard devia-
tion or as a percent as appropriate. Results between
groups were compared using the Student’s t test or the
Chi squared test. The Kolmogorov–Smirnov test was
conducted to verify the normal distribution of the con-
tinuous variables. Prior to further analysis, non-normal
distributed variables were log-transformed.

Linear regressions analyses were performed separately
by sex with a model with all predictors entered concur-
rently. HbA1c was used as the dependent variable. In-
dependent variables were the demographic and clinical
characteristics, as well as depression and anxiety symp-
toms. To avoid multicollinearity, the only antidiabetic
treatment variables considered were the combination
therapy with oral antidiabetic agents (OAA) and insulin
[23].

Results were considered statistically relevant when the
p-value was < 0.05 using a 95% confidence interval. SPSS
21.0 was used to carry out statistical analysis (SPSS Inc.,
Chicago, Illinois).

Results

Total sample

From July 2007 to July 2009 a total of 656 patients meet-
ing the inclusion criteria were identified. From these,
15 refused to participate (response rate = 97.7%). Their
demographic features were not different from those
included in the study. Due to missing data, 13 patients
were further eliminated. Therefore, this study com-
prised a clinic-based convenience sample of 628 persons
with T2DM, men representing 52.4%, aged 57.69 ± 5.55
(range 36–65 years) (Table 1).

Patients treated with insulin represented 58.7% of the
sample, and 36.6% were also taking an OAA. The mean
HbA1c level was 8.69% (50 mmol/mol) (SD = 1.66).
Only 13.4% of the patients had an HbA1c level below 7%
Depressive symptoms and other predictors of metabolic control by sex

Glycemic control was positively associated with depressive symptoms (standard beta = 0.12, significant p = 0.031) and negatively associated with comorbidities (standard beta = −0.13, significant p = 0.020) in women. A positive significant association with higher HbA1c was found with combined treatment with OAA and insulin (standard beta = 0.16, p = 0.003) in men. A younger age was significantly associated with poorer glycemic control both in men (standard beta = −0.24, p = < 0.001) and women (standard beta = −0.19, p = 0.002) (Table 2).

Discussion

This cross-sectional study evaluated the association of depressive symptoms and glycemic control by sex, adjusting for possible confounders, in a sample of patients with T2DM.

Globally participants had extremely poor glycemic control. The relatively low education level of the sample could account for this result. In a study by Mezuk et al. [24], subjects with major depressive disorder and low educational attainment had a higher risk of T2DM. However, in our study, neither in men nor in women was detected any association between education level and glycemic control. As socioeconomic status usually encompasses educational attainment and can be associated with suboptimal preventive care and unhealthy lifestyle, if we had evaluated other features like income maybe we would have found an association with poorer glycemic control [25].

In our sample, women had poorer glycemic control than men as reported in previous studies [9]. Nonetheless, other studies describe similar HbA1c values in T2DM patients between sexes [9, 12, 15]. In our study, a statistically significant association was found in women between depressive symptoms and poor glycemic control, adjusting for age and education level, diabetes duration, chronic complications, comorbidities, combined antidiabetic therapy and antidepressant use. No similar association was found for men.

Combined therapy was more often used in women, but was independently associated with poor glycemic control only in men. These findings could suggest that women were more responsive to combined treatment although their poor glycemic control.

Women were three times more likely to take antidepressants than men, but only half (15.7%) of the women diagnosed with depression were taking antidepressants. Some studies suggest that half of the T2DM patients are not accurately diagnosed for depressive symptoms [17, 26]. In a study by Katon et al., only a third of the patients with depression had been adequately treated with an anti-depressant for at least 3 months [17].

Prevalence of undiagnosed depression in both sexes may arise at least partly from the effects of depression on how people perceive their health. Li et al. found that

| Table 1 Data displayed represent the mean values ± standard deviation |
|---------------------------|-----------------|-----------------|-----------------|-----------------|
|                          | Total N = 628   | Men N = 329     | Women N = 299   | p-value        |
| Age (yrs)                | 57.69 ± 5.55    | 57.86 ± 5.34    | 57.50 ± 5.77    | 0.385          |
| Education level (yrs)    | 6.57 ± 3.87     | 6.84 ± 3.93     | 6.27 ± 3.78     | 0.035          |
| BMI (kg/m²)              | 29.99 ± 4.90    | 29.34 ± 4.55    | 30.70 ± 5.18    | 0.001          |
| Years from diagnosis     | 13.89 ± 7.59    | 13.56 ± 7.59    | 14.26 ± 7.59    | 0.089          |
| ≥ 2 chr complications    | 162 (25.8)      | 102 (31.0)      | 60 (20.1)       | 0.002          |
| ≥ 1 comorbidities        | 84 (13.4)       | 37 (11.2)       | 47 (15.7)       | 0.102          |
| OAA alone                | 259 (40.9)      | 157 (47.7)      | 100 (33.4)      | < 0.001        |
| Insulin alone            | 139 (22.1)      | 70 (21.3)       | 69 (23.1)       | 0.632          |
| OAA and insulin          | 230 (36.6)      | 102 (31.0)      | 130 (43.5)      | 0.001          |
| Antidepressant           | 64 (10.2)       | 17 (5.2)        | 47 (15.7)       | < 0.001        |
| HbA1c                    | 8.69 ± 1.66     | 8.41 ± 1.48     | 8.99 ± 1.79     | < 0.001        |
| HbA1c < 7                | 84 (13.4)       | 55 (16.7)       | 29 (9.7)        | 0.010          |
| HADS depression ≥ 8      | 153 (24.4)      | 50 (15.2)       | 103 (34.4)      | < 0.001        |

The respective percentage of the sample (global, men and women) is displayed between parentheses. Chi square and Student’s t-tests were used to compare each parameter between men and women. p-values are italic formatted when significance level is < 0.05. Chronic complications: retinopathy, nephropathy, neuropathy and cardiovascular
HADS The Hospital Anxiety and Depression Scale, BMI body mass index, OAA oral antidiabetic agent, HbA1c hemoglobin A1c

(53 mmol/mol). Depressive symptoms above the score threshold were present in 24.4%.

Sex differences

Women had significantly higher HbA1c values [mean = 8.99% (75 mmol/mol), SD = 1.79] than men [mean = 8.41% (69 mmol/mol), SD = 1.48] with a p-value = 0.0019. More men (16.7% men vs. 9.7% women, p = 0.010) reached significantly the therapeutic goal of HbA1c < 7% (53 mmol/mol). Women had significantly more depressive symptoms above the cut-off point (34.4% women vs. 15.2% men, p < 0.001). They are also three times more likely to take antidepressants than men (15.7% women vs. 5.2% men, significant p < 0.001). Men (31%) had more multiple (≥ 2) chronic complications than women (20.1%, significant p = 0.002). Women (43.5% vs. 31% men, p = 0.001) used significantly more combined therapy (OAA and insulin).

Depressive symptoms and other predictors of metabolic control by sex

Glob.
patients who reported poor or fair health had 2.8-fold greater likelihood of having undiagnosed depression [26].

Moreover, undiagnosed depression may be indirectly attributable to inability to correctly identify cases of depression as a function of sex. In a study based on a large British survey, men were more likely than women to misidentify depression in other men [27]. Beliefs such as hegemonic masculinity may affect men ability to self-report depression, leading them to report less symptoms overall than women. Nevertheless, one study found that men with higher adherence to masculine norms report more symptoms on measures of depression [28]. Another study showed that more than 20% of men who described themselves as depressed would not receive a diagnosis of depression by current criteria standards [29] suggesting the need for discussing traditional depression symptoms in what concern men.

In our study, similar to others results [15, 17, 18], men were less than half as likely to be depressed as women (34.4% women vs. 15.2% men, p < 0.001). The lower prevalence of depression in men may be attributable to underdiagnosis but we do not have any measure to declare or refute it.

**Conclusion**

Our study suggests that it may be clinically relevant to conduct a systematic screening for depressive symptoms in T2DM patients. Women who are under an optimized antidiabetic therapy and still have HbA1c values above the control cut-off point need to be systematically checked for depression. Treating depressive symptoms, especially in middle-aged women, enables better hyperglycemic control and avoids metabolic deterioration.

**Limitations**

This study has some limitations. Firstly, potential biological or psychological processes, link depression and T2DM. Hypothalamic–pituitary–adrenal axis, the innate immune response and the autonomic nervous system, and the burden with diabetes and unhealthy lifestyle behaviors, such as diet, physical activity and smoking [30], were not evaluated in our study. Secondly, the cross-sectional nature of the study does not allow for causality inferences. Chronic hyperglycemia can also affect depressive symptoms rather than vice versa, namely by the increase of diabetes burden [31]. Only with a longitudinal design would it be possible to determine the associative direction between hyperglycemia and depressive symptoms. Thirdly, depressive symptoms were analyzed with a Likert scale, but a psychiatric interview remains the gold standard for depression diagnosis in clinical practice.

Lastly, this represents a convenience sample from a single diabetes clinic with a population with poor glycemic control and low education level. Our findings may or may not be generalizable to other settings or patient populations.

Nevertheless, the large sample size is one of the study’s strengths. As far as we know, this is the first report to analyze the relationship between depressive symptoms and glycemic control in a Portuguese population with T2DM.

| Table 2 Multiple linear regressions analyses: associations of glycemic control and demographic, clinical and psychometric variables |
| --- |
| **Men** | Beta-S | t | p-value | **Women** | Beta-S | t | p-value |
| Age (yrs) | −0.24 | −4.28 | 0.001 | −0.19 | −3.20 | 0.002 |
| Education level (yrs) | −0.03 | −0.62 | 0.534 | −0.08 | −1.38 | 0.170 |
| BMII (kg/m²) | −0.07 | −1.32 | 0.187 | −0.01 | 0.13 | 0.896 |
| Years from diagnosis | 0.07 | 1.11 | 0.268 | 0.04 | 0.60 | 0.550 |
| ≥ 2 chr complications | 0.11 | 1.97 | 0.050 | 0.02 | 0.40 | 0.687 |
| ≥ 1 comorbidities | 0.10 | 1.90 | 0.059 | −0.13 | −2.33 | 0.020 |
| OAA and insulin | 0.16 | 3.14 | 0.003 | 0.10 | 1.75 | 0.081 |
| Antidepressant | 0.02 | 0.86 | 0.776 | 0.12 | 1.77 | 0.031 |
| HADS depression | −0.01 | −0.11 | 0.985 | 0.10 | 1.75 | 0.081 |
| Adjusted R² | 0.079 | 0.065 |
| F-change | 4.119 | 3.289 |
| p-value (F-change) | < 0.001 | 0.001 |

Beta-S: Beta standard regression coefficients. Statistically significant results with p-values < 0.05 are highlighted in italics. Chronic complications: retinopathy, nephropathy, neuropathy and cardiovascular HADS The Hospital Anxiety and Depression Scale, BMI body mass index, OAA oral antidiabetic agent
Abbreviations
T2DM: type 2 diabetes mellitus; T1DM: type 1 diabetes mellitus; Hba1c: hemoglobin A1c; APDP: Portuguese Diabetes Association; BMI: body mass index; HADS: Hospital Anxiety Depression Scale; OAA: oral antidiabetic agents.

Authors’ contributions
CG made substantial contributions to conception and design of the study and has been involved in drafting the manuscript. JRF analyzed and interpreted the patient data regarding the diabetes clinical evaluation. IC has been involved in collecting the patient data and was a major contributor in writing the manuscript. TAD has been involved in analysis and interpretation of data as well as in critically revising the manuscript for important intellectual content. SP has been involved in critically revising the manuscript. AB has been involved in the conception and design of the study. All authors read and approved the final manuscript.

Author details
1 Serviço de Psiquiatria e Saúde Mental do Hospital de Santa Maria–Centro Hospitalar Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal.
2 Faculdade de Medicina da Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisbon, Portugal.
3 Associação Protectora dos Diabéticos de Portugal (APDP), R. Rodrigo da Fonseca 1, 1250-189 Lisbon, Portugal.
4 NOVA Medical School-Faculdade de Ciências Médicas, Campo Mártires da Pátria 130, 1169-006 Lisbon, Portugal.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The data that support the findings of this study are available from Portuguese Diabetes Association but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Portuguese Diabetes Association.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Portuguese Diabetes Association on 29 March of 2007. Informed signed consent was obtained from all eligible participants who accepted to participate. The authors declare that the procedures followed the regulations established by the local Ethics Committee of the Portuguese Diabetes Association and the Helsinki Declaration of the World Medical Association.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 28 October 2017 Accepted: 9 January 2018
Published online: 16 January 2018

References
1. Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012;142(5):58–21.
2. Arnetz B, Ekberg NR, Alvåsron M. Sex differences in type 2 diabetes: focus on disease course and outcomes. Diabetes Metab Synd Obes. 2014;7:409–20.
3. Gardete-Correia L, Boavida JM, Raposo JF, Mesquita AC, Fona C, Carvalho R, et al. First diabetes prevalence study in Portugal: PREVADIAB study. Diabet Med. 2010;27:879–81.
4. Caldas de Almeida JM, Xavier M. Estudio Epidemiológico Nacional de Saúde Mental-1 relatorio: FCM–UNL. 2014.
5. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–8.
6. Margolis KL, Bonds DE, Rodobahy RJ. Effect of oestrogen plus progesterin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004;47:1175–87.
7. Schmidt PJ, Rubinow DR. Sex hormones and mood in the perimenopause. Ann NY Acad Sci. 2009;1179:70–85.
8. Gafvels C, Wåndell PE. Coping strategies in men and women with type 2 diabetes in Swedish primary care. Diabetes Res Clin Pract. 2006;71:280–9.
9. Kacerovsky-Bieleisz G, Lienhardt S, Hagenhofer M. Sex-related effects on metabolic control in type 2 diabetes mellitus. Diabetologia. 2009;52:781–8.
10. Mora R, Lager L. Ethnic and gender differences in psychosocial factors, glycemice control, and quality of life among adult type 2 diabetic patients. J Diabetes Complicat. 2009;23:54–64.
11. McGill JB, Majnic A, Knutsen PG. Effect of gender on treatment outcomes in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2013;102:167–74.
12. Kinder S, Carnethon MR, Palaniappan LP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med. 2004;66:316–22.
13. Muhtz C, Zyrax BC, Kla T. Depression symptoms and metabolic risk: effects of cortisol and gender. Psychoneuroendocrinology. 2009;34:1004–11.
14. Toker S, Shiroi A, Melamed S. Depression and the metabolic syndrome: gender-dependent associations. Depress Anxiety. 2008;25:661–9.
15. Cherrington A, Wallston KA, Rothman RL. Exploring the relationship between diabetes self-efficacy, depression symptoms, and glycemic control among men and women with type 2 diabetes. J Behav Med. 2014;37:381–9.
16. Lloyd CE, Dyert PH, Barnett AH. Prevalence of symptoms of depression and anxiety in a diabetes clinic consultation. Diabet Med. 2000;17:198–202.
17. Katon WJ, Simon G, Russo J, Bush T, Korff Von, Lin EHB, et al. Quality of depression care in a population-based sample of patients with diabetes and major depression. Med Care. 2004;42:1222–9.
18. Power F, Snoeck FJ. Association between symptoms of depression and glycaemic control may be unstable across gender. Diabet Med. 2001;18:595–9.
19. Legato MJ, Gelzer A, Golan R. The writing group for the partnership for gender-specific medicine: gender-specific care of the patient with diabetes: review and recommendations. Gend Med. 2007;3(2):131–58.
20. Goya C, Dias W, Camo I, Duarte R, Barbosa A. Treatment response in type 2 diabetes patients with major depression. Clin Psychol Psychother. 2014;21(1):39–48.
21. Pais-Ribeiro J, Silva I, Ferreira T. Validation study of a Portuguese version of the hospital anxiety and depression scale. Psychol Health Med. 2007;12(2):225–37.
22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.
23. Katz M. Multivariable analysis: A practical guide for clinicians. 2nd ed. Cambridge: Cambridge University Press, 2007.
24. Mezuk B, Eaton W, Golden SH, Ding Y. The influence of educational attainment on depression and risk of type 2 diabetes. Am J Public Health. 2008;98:1480–5.
25. Chan J, Nan H, Ting H. Depression and Diabetes: Socio-demographic and Cultural Aspects and Public Health Implications. In: Katon W, Maj M, Sartorius N, editors. Diabetes and depression. New York: Wiley; 2010. p. 143–71.
26. Li C, Ford ES, Zhao G, Mokdad A. Prevalence and correlates of undiagnosed depression among US adults with diabetes: the behavioral risk factor surveillance system. Diabetes Res Clin Pract. 2009;83:268–79.
27. Swami V. Mental health literacy of depression: gender differences and attitudinal antecedents in a representative British sample. PLoS ONE. 2012;7(11):e49779. https://doi.org/10.1371/journal.pone.0049779.
28. Berger JL, Addis ME, Reilly ED, Syzdek MR, Green JD. Effects of gender, diagnostic labels, and causal theories on willingness to report symptoms of depression. J Soc Clin Psychol. 2012;31(5):439–57.
29. Nadeau MM, Balsam MJ, Rochlen AB. Men’s depression: endorsed experiences and expressions. Psychol Men Masc. 2016;17(4):328–35.
30. Ismail K. Unraveling the pathogenesis of the depression-diabetes link. In: Katon W, Maj M, Sartorius N, editors. Diabetes and depression. New York: Wiley; 2010. p. 30–61.
31. Rubin RR. Stress and depression in diabetes, Clinical diabetes. Clin Diabetes. 2006;21:269–80.